Braxia Scientific has dosed the first patients in its multi-dose psilocybin clinical trial exploring the compound’s efficacy for treatment-resistant depression (TRD).
Wesana Health and MAPS have announced the receipt of a commercial viability analysis conducted by the Boston Consulting Group (BCG) which will bring the parties closer...
Positive outcomes for the use of psilocybin therapy in conjunction with SSRIs have been reported from COMPASS Pathways’ Phase IIb trial.
Psyched Wellness presented its proprietary extract of the Amanita Muscaria mushroom, AME-1, to Health Canada representatives to discuss the evidence required in support of a Class...
Ketamine One Capital and Cognetivity Neurosciences have entered into a partnership to study and develop assessments for depression and post-traumatic stress disorder (PTSD).
MYND has received the funding that will go towards its research and development into the effects of psilocybin for treating brain and central nervous system diseases.
The US Food and Drug Administration (FDA) has given authorisation for a Phase II clinical trial to evaluate psychedelic-assisted psychotherapy for frontline clinicians who are experiencing...
Findings from a new study give insight into how psychedelic substances may relieve symptoms of mental health conditions.
Clearmind Medicine has signed an R&D agreement with Bar-Ilan University to explore the efficacy of its compound for the treatment of addiction.
New findings from a citizen science study suggest that microdosing psychedelics could be a valuable tool in the battle against poor mental health.